RO-7656594
- Generic Name
- RO-7656594
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
Phase 1
Recruiting
- Conditions
- Advanced Prostate CancerMetastatic Prostate Cancer
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT05800665
- Locations
- 🇺🇸
Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath